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Polymeric cytotoxic conjugates are being developed with the aim of preferential delivery of the anticancer agent to tumour. MAG-
CPT comprises the topoisomerase I inhibitor camptothecin linked to a water-soluble polymeric backbone methacryloylglycynamide
(average molecular weight 18kDa, 10% CPT by weight). It was administered as a 30-min infusion once every 4 weeks to patients with
advanced solid malignancies. The objectives of our study were to determine the maximum tolerated dose, dose-limiting toxicities,
and the plasma and urine pharmacokinetics of MAG-CPT, and to document responses to this treatment. The starting dose was
30mgm
 2 (dose expressed as mg equivalent camptothecin). In total, 23 patients received 47 courses at six dose levels, with a
maximum dose of 240mgm
 2. Dose-limiting toxicities were myelosuppression, neutropaenic sepsis, and diarrhoea. One patient died
after cycle 1 MAG-CPT at the maximum dose. The maximum tolerated dose and dose recommended for further clinical study was
200mgm
 2. The half-lives of both MAG-CPT and released CPT were prolonged (46 days) and measurable levels of MAG-CPT
were retrieved from plasma and urine 4 weeks after treatment. However, subsequent pharmacodynamic studies of this agent have
led to its withdrawal from clinical development.
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Camptothecin (CPT) is the prototypic inhibitor of topoisomerase I.
Although it was discovered in the 1970s, its clinical development
was prevented by failure to devise a suitable formulation for this
compound and the unpredictable and severe toxicity observed in
early clinical trials, in particular myelosuppression, gastrointest-
inal toxicity, and haemorrhagic cystitis (Gottlieb et al, 1970;
Muggia et al, 1972). In retrospect it is probable that these studies
used mainly the open ring form of CPT, which is a relatively poor
inhibitor of topoisomerase I but is more soluble than the active
CPT lactone (Rivory and Robert, 1995). There is some conversion
of the open form to CPT lactone in plasma and this explains much
of the toxicity and the antitumour activity that was seen in these
trials. The bladder toxicity is explained by conversion of the open
ring to the closed ring form when CPT, which has been cleared by
the kidneys, is exposed to low pH in the urine. It is all the more
remarkable that despite these problems responses to CPT were
observed in colorectal cancer, small bowel carcinoma, and
melanoma in early clinical trials.
PNU-166148 (MAG-CPT) is a copolymer of N-(hydroxypropyl)
methacrylamide, (20-O-(N-methacryloyl-glycyl-aminohexanoyl-
glycyl)) camptothecin and N-(2-hydroxypropyl) methacryloyl
glycinamide, which was developed by Pharmacia and Upjohn in
an attempt to overcome problems in the clinical delivery of CPT.
This polymeric derivative of CPT was designed specifically to
increase cytotoxic drug delivery to the tumour. The macromole-
cule should preferentially accumulate within tumour tissue
through extravasation via the abnormal tumour vasculature. The
active but insoluble closed ring CPT molecule is covalently linked
to the soluble MAG polymer through a glycyl-aminohexanoyl-
glycyl spacer. The presence of this spacer modulates the
intratumour release of CPT, requiring hydrolysis of the ester
linkage which is pH and enzyme dependent, and may result in
prolonged exposure of the tumour to low levels of CPT (Figure 1)
(Conover et al, 1999).
Preclinical studies of MAG-CPT have shown that this compound
is active in colon, stomach, pancreas, ovary, breast, lung, and
melanoma xenograft models. The predicted delivery of the
cytotoxic to tumour was confirmed in xenograft-bearing mice,
with tumour concentrations of CPT exceeding plasma levels three
days after a single i.v. treatment (Conover et al, 1998; Caiolfa et al,
2000). Toxicological studies in animals confirmed that the major
toxicities of this compound were myelosuppression, diarrhoea,
and transient impairment of renal and hepatic function.
The clinical development of MAG-CPT was driven by the
combined promise of the established cytotoxic effect of CPT-
mediated inhibition of topoisomerase I and the potential for
enhanced delivery of CPT to tumour through a polymer delivery
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lsystem. The principal objectives of this phase I study were (i) to
determine the safety profile of MAG-CPT when administered as a
single 30-min infusion every 4 weeks to adult patients with solid
tumours; (ii) to determine the maximum tolerated dose (MTD)
and recommend a safe starting dose on this schedule for phase II
studies of MAG-CPT; (iii) to characterise the pharmacokinetic
profile of MAG-CPT in terms of carrier-bound CPT and released-
CPT; and (iv) to describe any antitumour activity observed in this
phase I trial.
PATIENTS AND METHODS
This was an open-label nonrandomised dose escalation study,
conducted in sequential cohorts of patients from two institutions,
Aberdeen Royal Infirmary, Aberdeen, and the Beatson Oncology
Centre, Glasgow. It was performed under the auspices of the
Cancer Research Campaign, London, with sponsorship by
Pharmacia and Upjohn, Milan.
Eligibility
All patients had histologically or cytologically proven advanced
solid malignancy that was refractory to conventional therapy.
Study entry criteria included age X18 years, life expectancy of at
least 12 weeks, adequate bone marrow reserves (absolute
neutrophil count (ANC)X2000ml
 1, platelets X100000ml
 1), liver
function tests (total bilirubin, AST and ALT) within normal limits
unless known liver metastases when total bilirubin p1.5 times
upper limit of normal (NCI CTC grade 1), AST and ALT p5 times
upper limit of normal (NCI CTC grade 2), and adequate renal
function (serum creatinine o1.5mgdl
 1, EDTA clearance
460mlmin
 1). The following exclusion criteria were applied:
serious coexisting medical condition that could limit full
compliance with the study, haematological malignancies, pregnant
or breast feeding women, or fertile persons refusing to use
contraceptives, known brain or leptomeningeal disease, previous
treatment with irinotecan, more than two prior chemotherapeutic
regimens for metastatic disease, high-dose chemotherapy requir-
ing bone marrow transplantation or peripheral blood stem cell
support, or radiotherapy to more than 25% of the bone marrow.
All patients gave written informed consent according to local
Ethics Committee guidelines.
Drug administration and dosage
MAG-CPT has an average molecular weight of 18kDa, polydis-
persity (Mw/Mn) 1.4, with o0.01 free CPT (wt%). The drug was
supplied by Pharmacia and Upjohn as a sterile freeze dried powder
for injection packaged in glass vials containing 0.5g of MAG-CPT
(equivalent to 50mg of CPT). All doses of the investigational agent
are expressed as mg of CPT equivalent. The drug was stored
at room temperature. The vials were reconstituted with 10ml
normal saline and the dose to be administered was made up
in 100ml saline in a PVC infusion bag. A volumetric pump was
used to deliver MAG-CPT as a 30-min i.v. infusion on day 1 of a
28-day cycle.
The starting dose for the study was 30mgm
 2, approximately
one-tenth of the LD10 in mice. It was planned that dose escalation
should proceed by 100% increments until the first occurrence of
any NCI CTC Grade 2 drug-related toxicity (or Grade 1
neurotoxicity) was observed in the first treatment cycle. There-
after, dose escalation was to continue according to a modified
Fibonacci series. The dose escalation scheme could, however, be
modified if considered appropriate based on acquired clinical and
pharmacokinetic data. The MTD was defined as the highest dose
at which at least three of six patients had dose-limiting
toxicity (DLT). DLT was defined as (i) grade 2 neurotoxicity or
grade 3 or 4 other nonhaematological toxicity, excluding grade 3 or
4 nausea or vomiting in patients who had not received a full
antiemetic regimen (prophylactic antiemetics were not given in
cycle 1), (ii) platelets o25000ml
 1, (iii) grade 4 neutropaenia
(ANC o500ml
 1) of at least 5 days duration or associated with
fever (4381C), or (iv) treatment delay exceeding 2 weeks caused
by unresolved toxicity.
Patients were to be retreated at 28-day intervals for up to six
cycles. A new course of treatment could begin if the ANC
X2000ml
 1 and platelets X100000ml
 1 and all other treatment-
related toxicities had resolved to p grade 1 (grade 0 neurotoxi-
city). Treatment could be delayed for up to 2 weeks to allow
resolution of toxicity. Escalation of MAG-CPT dose was not
allowed for individual patients on the study. For patients with
dose-limiting haematological toxicity in whom further treatment
cycles were deemed appropriate these were to be given at the lower
previous dose level.
Prophylactic treatment with antiemetics was not permitted
during the first cycle of treatment unless nausea and vomiting
that was clearly drug related had been observed at previous dose
levels. Prophylactic growth factor support was not allowed.
Patients requiring palliative radiotherapy were to be removed
from the trial.
Patients were to be withdrawn from study if they completed six
treatment cycles, developed progressive disease, failed to recover
from toxicity despite a 2-week delay in therapy, if changes in their
medical status made them no longer eligible for the study, or at the
discretion of the investigator, or at the request of the patient.
Pretreatment and on-treatment assessments
Prior to treatment all patients had a complete medical history and
physical examination, FBC, serum chemistry, urinalysis, EDTA
clearance, 12 lead ECG, chest X-ray, and tumour assessment by
physical examination, CT scan, or ultrasonography as appropriate.
During the course of the study patients were reviewed in the clinic
every week with toxicity assessment, physical examination, FBC,
and serum chemistry. Tumour assessment by imaging was
repeated every three cycles. Chest X-ray and ECG were repeated
at the end of study.
Figure 1 Structure of MAG-CPT. Free camptothecin is released by
hydrolysis, which converts (B)t o( A).
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lPharmacokinetics
Blood samples were taken from all patients following their first
course of MAG-CPT predose, halfway through infusion, at the end
of infusion, and at 10min, 30min, 1h, 2h, 4h, 8h, between 10 and
16, 24, and 48h after the end of infusion. Further blood samples
were taken at weekly intervals while the patients remained on
study. For each sample two aliquots of plasma were separated,
stored at  201C, and shipped on dry ice to Pharmacia and Upjohn,
Milan, for the analysis.
A high-performance liquid chromatographic (HPLC) method
with fluorescence detection was used for the determination of CPT
(intact lactone and carboxylate) concentrations as CPT released in
vivo from MAG-CPT (denoted as released-CPT) and, indirectly, as
CPT bound to the carrier (denoted carrier-bound CPT) (Schoe-
maker et al, 2001). The carrier-bound CPT concentrations
(expressed as ngeqCPT/ml) were obtained by subtracting the
released CPT levels from the total levels of CPT obtained after
alkaline hydrolysis of MAG-CPT. To avoid release of CPT during
sample manipulation, the aliquot of plasma used for the
determination of released CPT was immediately acidified. Plasma
pharmacokinetic parameters of both carrier-bound and released-
CPT were calculated using noncompartmental methods with the
aid of WinNonlin (version 2.1, Scientific Consulting Inc., 1996).
Descriptive statistics (mean, s.d.) were calculated for plasma levels
at each time point and for pharmacokinetic parameters calculated
after each dose level.
Urine samples were collected from all patients on the day of
drug administration following the first course of MAG-CPT and
weekly thereafter. Urine samples, stored at  201C, were shipped
on dry ice to Pharmacia and Upjohn, Milan, for the determination
of total CPT by HPLC.
RESULTS
A total of 23 patients were registered between January 1999 and
April 2000, and their characteristics are outlined in Table 1. They
received 47 courses of MAG-CPT through six dose levels ranging
from 30 to 240mgm
 2, and all courses were fully assessable for
toxicity. The number of cycles delivered at each dose level is
summarised in Table 2. The median number of cycle administered
per patient was 2 (range 1–6). All treatment cycles were
administered on time at the planned dose with the exception of
cycle 2 in two patients treated at 240mgm
 2 when a 50% dose
reduction was applied because of DLT in cycle 1.
No significant drug-related toxicities were noted at the 30, 60, or
120mgm
 2 dose levels, allowing dose escalations of 100%. Dose-
limiting haematological and nonhaematological toxicities were
observed in all three patients treated at 240mgm
 2. Subsequent
cohorts of patients were treated at intermediate dose levels of 170
and 200mgm
 2 in order to define a safe dose for phase 2 studies.
Toxicities
Nausea and vomiting grade 1 was observed sporadically through
dose levels 30–120mgm
 2. No other significant treatment-related
toxicities were observed at these dose levels.
The first patient treated at 240mgm
 2 had extensive metastatic
colorectal carcinoma with lung and liver metastases. His prior
therapy included adjuvant 5FU and folinic acid chemotherapy,
pelvic radiotherapy, further chemotherapy with 5FU and folinic
acid for metastatic disease, and palliative radiotherapy for rib
metastases. Following cycle 1 MAG-CPT he developed grade 4
myelosuppression and grade 2 diarrhoea. He was admitted on day
12 with neutropaenic sepsis (WCC 0.07ml
 1) and thrombocyto-
paenia (platelets 1ml
 1). He deteriorated rapidly despite suppor-
tive care with i.v. antibiotics, platelets, and blood transfusion (Hb
9.0gdl
 1 on admission). He died of multiorgan failure less than
24h after admission.
The second patient treated at this dose level had malignant
mesothelioma. Following cycle 1 she developed grade 3 diarrhoea
and grade 3 myelosuppression. She was also admitted with
neutropaenic sepsis (nadir neutrophils 0.85ml
 1, platelets 88ml
 1
on day 10), but rapidly recovered from this with supportive care
and i.v. antibiotics. Haematological toxicity had completely
resolved by day 22. She received a second cycle of MAG-CPT at
a reduced dose (120mgm
 2) with no drug-related toxicity of note.
The third patients treated at 240mgm
 2 had metastatic squamous
carcinoma of unknown primary. Following cycle 1 she had grade 3
diarrhoea with no myelosuppression. In view of the toxicity
experienced by the previous two patients, she was also retreated at
Table 1 Patients characteristics
Characteristic Number
No. of patients 23
No. of assessable courses 47
Median 2
Range 1–6
Sex
Male 15
Female 8
Age
Median 62
Range 33–75
ECOG performance status
05
11 8
20
Prior therapy
Chemotherapy 21
Radiotherapy 13
Hormone therapy 2
Tumour type
Colorectal 6
Unknown primary 4
Head and neck 2
NSCLC 2
Renal 2
Adrenal 1
Cervical 1
Oesophageal 1
Ewing’s 1
Gastric 1
Mesothelioma 1
Prostatic 1
Table 2 Dose levels and cycles of MAG-CPT delivered
Dose level
(mgm
 2)
% Dose
increment
No. of
patients
No. of
cycles Dose reductions
30 3 2,1,2
60 100 3 1,3,1
120 100 3 2,3,2
240 100 3 1,1,1 Two patients re-treated
at 120mgm
 2
170  30 3 2,1,2
200 18 8 2,2,6,1,2,1,2,1
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 2 and had no further drug-related
toxicity of note. The MTD for MAG CPT in this study was therefore
240mgm
 2.
No significant drug-related toxicity was observed in the three
patients treated at 170mgm
 2. Only one of the eight patients
treated at 200mgm
 2 had grade 2 dysuria and haematuria during
cycle 2. No significant haematological toxicity occurred at either of
these intermediate dose levels. Accordingly, 200mgm
 2 was the
dose recommended for phase II studies.
Antitumour activity
No objective antitumour responses were seen. At 60mgm
 2,
regression of cutaneous metastases was observed in a patient with
renal carcinoma. However, this patient had progressive disease
with the development of brain metastases.
Pharmacokinetics
The main pharmacokinetic parameters for both carrier-bound and
released-CPT at all dose levels are summarised in Tables 3 and 4.
Figure 2 shows mean (s.d.) plasma concentration time curves of
both compounds for patients treated at 200mgm
 2. Carrier-bound
CPT was characterised by low clearance and a volume of
distribution of the same order as the volume of biological fluids.
Plasma pharmacokinetic parameters of carrier-bound CPT
appeared dose independent over the range of tested dose levels.
The Cmax for released CPT was achieved about 24h after dosing
at each dose level. After the peak, released-CPT levels decayed with
a terminal half-life similar to that of carrier-bound drug (range
97–291h). Plasma levels of released-CPT accounted for 0.01–4.9%
of carrier-bound drug concentrations (median 0.28%). Carrier-
bound CPT and released-CPT AUC0 N as a function of dose
are reported in Figure 3. Overall, no substantial deviation from
dose proportionality was apparent. Both carrier-bound and
released-CPT were detectable in plasma up to 4 weeks after
treatment. However, in patients who received multiple cycles of
MAG-CPT there was no evidence of drug accumulation. Following
cycle 2 MAG-CPT at 200mgm
 2, the mean plasma level of
released-CPT decreased from 0.113mgml
 1 on day 8 to
0.025mgml
 1 on day 29.
Table 5 summarises the data on the amount of total CPT
excreted in the urine within 24h of treatment with MAG-CPT. At
all doses tested, on average, at least 50% of the administered dose
of total CPT was recovered in the urine during the first 24h. Drug
could be detected at all dose levels in the urine of most patients 28
days postdosing. In patients treated at 200mgm
 2 the mean
urinary concentration of total CPT decreased from 2.8mgml
 1 in
week 2 to 0.5mgml
 1 in week 4 of the first treatment cycle.
DISCUSSION
This study has shown that it is possible to deliver higher doses of
camptothecin as a polymeric derivative compared with the parent
compound. Moreover, at the recommended dose of 200mgm
 2,
the toxicities of MAG-CPT were predictable and manageable. The
Table 3 Pharmacokinetic parameters of carrier-bound CPT in plasma following cycle 1 MAG-CPT
Dose (mgm
 2) Cend inf (lgml
 1) t1/2Z (h) AUC0– (lghml
 1)C L ( m l h
 1m
 2) Vss (mlm
 2)
30 15.5 (3.8) 216 (22) 976.2 (163.7) 31.4 (5.8) 7841 (1903)
60 30.4 (1.6) 132 (49) 1760.7 (533.6) 36.2 (10.6) 5297 (529)
120 64.0 (8.4) 219 (16) 5747.6 (596.9) 21.0 (2.1) 5710 (722)
170 78.6 (3.6) 188 (29) 6559.1 (497.9) 26.0 (1.9) 6289 (524)
200 111.9 (35.2) 237 (37) 9305.3 (2170.5) 22.3 (4.7) 6481 (1883)
240 126.7 (21.5) 155 (n¼2) 10667.5 (n¼2) 23.0 (n¼2) 4326 (n¼2)
Values are mean (standard deviation). Cend inf¼concentration at the end of infusion; AUC0 N¼area under the plasma concentration vs time curve extrapolated to infinite time;
CL¼systemic clearance; Vss¼volume of distribution at steady state; t1/2z¼apparent terminal half-life.
Table 4 Pharmacokinetic parameters of released-CPT in plasma following cycle 1 MAG-CPT
Dose (mgm
 2) Cmax (lgml
 1) Tmax (h) t1/2Z (h) AUC0–N (lghml
 1)
30 0.060 (0.039) 25 (0) 168 (107) 10.0 (4.5)
60 0.141 (0.087) 25 (0) 185 (97) 24.3 (12.0)
120 0.196 (0.079) 15 (9) 216 (58) 37.8 (20.0)
170 0.127 (0.023) 25 (0) 224 (23) 31.5 (10.8)
200 0.230 (0.133) 25 (11) 209 (64) 43.8 (25.5)
240 0.589 (0.105) 28 (19) 228 (n¼2) 73.3 (n¼2)
Values are mean (standard deviation). Cmax¼maximum concentration; Tmax¼time to maximum concentration; AUC0–N¼area under the plasma concentration vs time curve
extrapolated to infinite time; t1/2z¼apparent terminal half-life.
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Figure 2 Mean (s.d.) plasma concentration–time curves of carrier-
bound CPT and released-CPT following 200mgm
 2 dose.
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ldose-limiting side effects that were observed in this study, mainly
myelosuppression and diarrhoea, were those predicted from
preclinical toxicology. However, the highest dose of 240mgm
 2
is clearly above the tolerable dose of MAG-CPT with all three
patients experiencing life-threatening toxicities. From the experi-
ence outlined in this study we would recommend that the
appropriate dose for Phase II studies of MAG-CPT is 200mgm
 2
once every 4 weeks.
The design of this compound was intended to result in
preferential and prolonged exposure of the tumour to camptothe-
cin with relatively low levels of normal tissue drug exposure. MAG-
CPT does result in some interesting changes in the pharmacoki-
netics of camptothecin with a prolonged half-life for both carrier-
bound and released-CPT. It is however not clear from this study
whether this translates into a pharmacodynamic benefit, and
certainly no sign of significant antitumour activity was observed in
this study. The toxicities observed within this study, namely
myelosuppression, neutropaenic sepsis, and diarrhoea, were
similar to those observed with the parent compound camptothe-
cin.
This is the second clinical study of MAG-CPT to be reported.
The earlier study examined an alternative schedule of delivery,
with treatment on the first 3 days of a 28-day cycle (Schoemaker
et al, 2002). Neither myelosuppression nor diarrhoea was dose
limiting in this study. Instead bladder toxicity, with dysuria and
haematuria, was dose limiting at 130mgm
 2day (390mgm
 2 per
4 week cycle). There was no evidence of antitumour activity of
MAG-CPT in this trial.
Several macromolecular systems have been developed with a
cytotoxic drug complexed or covalently bound to the carrier. In
preclinical studies this approach clearly alters the pharmacoki-
netics of the cytotoxic but also enhances drug delivery to the
tumour, a phenomenon termed the Enhanced Permeability and
Retention (EPR) effect (Matsumura and Maeda, 1986; Seymour,
1992). It is thought that EPR is due to the discontinuous nature of
the tumour endothelium allowing extravasation of the macro-
molecule and also the lack of effective lymphatic drainage within
the tumour. The first such cytotoxic-copolymer conjugate to
undergo clinical evaluation was PK1. This comprises doxorubicin
bound to the water-soluble N-(2-hydroxypropyl) methacrylamide
copolymer by a peptidyl linker. This markedly altered the
pharmacokinetics of doxorubicin and allowed several fold higher
doses of doxorubicin to be administered compared with the parent
compound (Vasey et al, 1999). In particular, there was no evidence
of cardiotoxicity and no polymer-related toxicities. The EPR effect
was demonstrated for this compound in the clinical trial, when
radiolabelled drug was demonstrated to accumulate within
tumour. Moreover, PK1 showed evidence of activity in refractory
cancers in the phase I trial.
MAG-CPT differs from PK1 with regard to its polymer and
spacer as well as the cytotoxic moiety, but the aim of its design was
similar, namely to achieve preferential delivery of the cytotoxic
into tumour tissue. The observed toxicities in the two clinical trials
of MAG-CPT may be explained by hydrolysis of the ester linkage
between CPT and polymer either in blood or during urinary
excretion, exposing normal tissues to free CPT. In contrast, the
peptidyl linker of PK1 was designed for intratumoural cleavage by
lysosomal cysteine proteases and appears successful in this role
(Duncan et al, 2001).
At the time of completion of the phase I studies of MAG-CPT, a
‘proof of principle’ trial was initiated by Pharmacia in order to
measure the delivery of camptothecin to tumour by MAG-CPT. A
total of 10 patients with localised colorectal cancer received a
single dose of MAG-CPT 60mgm
 2 up to 7 days prior to elective
surgery for resection of their primary tumour (Sarapa et al, 2003).
Carrier-bound and released-CPT were measured in plasma,
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Figure 3 Mean (s.d.) AUC0 N of carrier-bound CPT (upper panel) and
released-CPT (lower panel) as a function of dose.
Table 5 Urinary parameters of total CPT following cycle 1 MAG-CPT
Time interval 0–8h 8–24h 0–24h
Dose (mgm
 2) Ae (mg) fe (% dose) Ae (mg) fe (% dose) Ae (mg) fe (% dose)
30 31.1 (5.2) 58.4 (5.6) 10.2 (1.8) 19.1 (1.7) 41.3 (7.0) 77.5 (7.3)
60 42.6 (13.2) 37.7 (10.3) 18.9 (4.6) 17.5 (7.6) 61.6 (9.2) 55.2 (11.8)
120 133.0 (52.4) 59.4 (23.6) 36.5 (21.5) 16.5 (10.0) 169.5 (64.1) 76.0 (29.5)
170 125.1 (49.2) 39.0 (16.2) 46.1 (18.5) 14.0 (5.2) 171.2 (47.3) 53.0 (15.3)
200 322.8 (178.7) 30.5 (7.5) 97.8 (51.2) 25.7 (15.0) 193.6 (29.4) 49.3 (5.3)
240 777.8 (659.6) 45.3 (26.1) 104.6 (92.1) 22.4 (18.7) 309.3 (59.3) 67.7 (9.5)
Values are mean (standard deviation). Ae¼amount of total CPT excreted in urine. For each time interval this was calculated as the product of the measured urinary
concentration and the urinary volume; fe¼amount of total CPT excreted in urine expressed as percentage of dose administered.
Phase I study MAG-CPT
D Bissett et al
54
British Journal of Cancer (2004) 91(1), 50–55 & 2004 Cancer Research UK
C
l
i
n
i
c
a
ltumour, and adjacent normal bowel. Although MAG-CPT was
delivered in measurable concentration to the tumour, disappoint-
ingly the concentrations of released CPT were consistently lower in
tumour than in normal colon. In addition, the concentration of
CPT in blood exceeded that within the tumour even at 7 days after
injection, and there was no evidence of preferential retention of the
cytotoxic within the tumour. Based on the results of the phase I
studies and the intratumoural kinetic study, Pharmacia made a
strategic decision to discontinue further clinical development of
MAG-CPT. However, development of other therapeutic molecules
with polymeric delivery systems continues and it seems likely that
the clinical promise of this approach will be fulfilled in the future.
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